This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Molla, A. Articles by Kempf, D. J. Search for Related Content PubMed PubMed Citation Articles by Molla, A. Articles by Kempf, D. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2002, p. 2249-2253, Vol. 46, No. 7
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.7.2249-2253.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vitro Antiviral Interaction of Lopinavir with Other Protease Inhibitors

Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois

Received 19 October 2001/ Returned for modification 9 January 2002/ Accepted 21 March 2002

The in vitro inhibition of wild-type human immunodeficiency virus (HIV) by combinations of lopinavir and six other protease inhibitors over a range of two-drug combination ratios was evaluated. Combinations of lopinavir with indinavir, nelfinavir, amprenavir, tipranavir, and BMS-232632 generally displayed an additive relationship. In contrast, a consistent, statistically significant synergistic inhibition of HIV type 1 replication with combinations of lopinavir and saquinavir was observed. Analysis of the combination indices indicated that lopinavir with saquinavir was synergistic over the entire range of drug combination ratios tested and at all levels of inhibition in excess of 40%. Cellular toxicity was not observed at the highest drug concentrations tested. These results suggest that administration of combinations of the appropriate dose of lopinavir with other protease inhibitors in vivo may result in enhanced antiviral activity with no associated increase in cellular cytotoxicity. More importantly, the observed in vitro synergy between lopinavir and saquinavir provides a theoretical basis for the clinical exploration of a novel regimen of lopinavir-ritonavir and saquinavir.

This article has been cited by other articles:

• van der Lugt, J., Autar, R. S., Ubolyam, S., Garcia, E. F., Sankote, J., Avihingson, A., Chuenyam, T., Cooper, D. A., Lange, J., Phanuphak, P., Wit, F., Ruxrungtham, K., Burger, D., on behalf of the HIV-NAT 019 Study Team, (2008). Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. J Antimicrob Chemother 61: 1145-1153 [Abstract] [Full Text]  
• Hazen, R., Harvey, R., Ferris, R., Craig, C., Yates, P., Griffin, P., Miller, J., Kaldor, I., Ray, J., Samano, V., Furfine, E., Spaltenstein, A., Hale, M., Tung, R., St. Clair, M., Hanlon, M., Boone, L. (2007). In Vitro Antiviral Activity of the Novel, Tyrosyl-Based Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor Brecanavir (GW640385) in Combination with Other Antiretrovirals and against a Panel of Protease Inhibitor-Resistant HIV. Antimicrob. Agents Chemother. 51: 3147-3154 [Abstract] [Full Text]  
• Vidal, F., Domingo, J. C., Guallar, J., Saumoy, M., Cordobilla, B., Sanchez de la Rosa, R., Giralt, M., Alvarez, M. L., Lopez-Dupla, M., Torres, F., Villarroya, F., Cihlar, T., Domingo, P. (2006). In Vitro Cytotoxicity and Mitochondrial Toxicity of Tenofovir Alone and in Combination with Other Antiretrovirals in Human Renal Proximal Tubule Cells. Antimicrob. Agents Chemother. 50: 3824-3832 [Abstract] [Full Text]  
• Murga, J. D., Franti, M., Pevear, D. C., Maddon, P. J., Olson, W. C. (2006). Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1.. Antimicrob. Agents Chemother. 50: 3289-3296 [Abstract] [Full Text]  
• Corbett, A. H., Patterson, K. B., Tien, H.-C., Kalvass, L. A., Eron, J. J., Ngo, L. T., Lim, M. L., Kashuba, A. D. M. (2006). Dose Separation Does Not Overcome the Pharmacokinetic Interaction between Fosamprenavir and Lopinavir/Ritonavir.. Antimicrob. Agents Chemother. 50: 2756-2761 [Abstract] [Full Text]  
• De Meyer, S., Azijn, H., Surleraux, D., Jochmans, D., Tahri, A., Pauwels, R., Wigerinck, P., de Bethune, M.-P. (2005). TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates. Antimicrob. Agents Chemother. 49: 2314-2321 [Abstract] [Full Text]  
• Ribera, E., Lopez, R. M., Diaz, M., Pou, L., Ruiz, L., Falco, V., Crespo, M., Azuaje, C., Ruiz, I., Ocana, I., Clotet, B., Pahissa, A. (2004). Steady-State Pharmacokinetics of a Double-Boosting Regimen of Saquinavir Soft Gel plus Lopinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Infected Adults. Antimicrob. Agents Chemother. 48: 4256-4262 [Abstract] [Full Text]  
• Bulgheroni, E., Citterio, P., Croce, F., Lo Cicero, M., Vigano, O., Soster, F., Chou, T.-C., Galli, M., Rusconi, S. (2004). Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. J Antimicrob Chemother 53: 464-468 [Abstract] [Full Text]